Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orthocell Ltd ( (AU:OCC) ) has provided an announcement.
Orthocell Limited has announced the terms and conditions for 950,000 options issued as part of a securities proposal. These options, divided into two tranches, are exercisable over a period of three to four years with specific conditions regarding their exercise and transferability. This announcement reflects Orthocell’s strategic financial maneuvers to enhance its market position and operational capabilities.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for dental and orthopedic applications, and products like Striate+™ and Remplir™ for dental GBR and peripheral nerve reconstruction, respectively. Orthocell is expanding its market reach with global distribution and is advancing its tendon cell therapy in the US.
Average Trading Volume: 883,671
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$325.6M
Learn more about OCC stock on TipRanks’ Stock Analysis page.